Stockwinners Market Radar for September 21, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:17 EDT Cathie Wood's ARK Investment bought 1.3M shares of Ginkgo Bioworks today

19:43 EDT Sempra Infrastructure unit receives FERC authorization at Port Arthur LNG - The company states: "Sempra Infrastructure, a subsidiary of Sempra, announced that the Federal Energy Regulatory Commission, FERC, has approved the permit authorizing the Port Arthur LNG Phase 2 expansion project under development at Port Arthur LNG in Jefferson County, Texas. The permit is a major regulatory milestone for a proposed Phase 2 project, including the addition of two liquefaction trains capable of producing up to 13 million tonnes per annum of liquefied natural gas. With Phase 1 currently under construction, the development of the proposed Phase 2 project could increase the total liquefaction capacity of the facility from approximately 13 Mtpa to approximately 26 Mtpa. The proposed project is also expected to include an additional LNG storage tank and marine berth and would benefit from some of the common facilities currently under construction that were previously approved as part of the Port Arthur LNG Phase 1 permitting process. Sempra Infrastructure continues to evaluate opportunities to develop the entirety of the Port Arthur site while also exploring potential projects to reduce the carbon intensity of its LNG, positioning Port Arthur as a flagship hub for the energy transition. The company is leveraging the integrated capabilities of its business segments to develop the proposed Port Arthur Pipeline Texas Connector project, the proposed Post Arthur Pipeline Louisiana Connector project and develop new gas storage facilities, all of which would serve the Port Arthur LNG facility."

19:09 EDT Zoom Video COO sells $920K in common stock - In a regulatory filing, Zoom Video disclosed that its COO Aparna Bawa 13.3K shares of common stock on September 19th in a total transaction size of $920K.

18:48 EDT Faraday Future announces management stock purchase plan - Faraday Future "announced that its future Global CEO Matthias Aydt, Founder & Chief Product and User Product Officer YT Jia, current Global CEO and future EVP of Global Industrialization & China CEO XF Chen, Interim CFO Jonathan Maroko, and Chief Accounting Officer Yun Han, along with other senior executives and members of management, have voluntarily entered into a salary deduction and stock purchase agreement. Subject to shareholder approval of the agreement as required by Nasdaq, these senior executives and members of management have committed to utilize 50% of their salary over a three-month period to purchase shares of the Company's Class A common stock from the Company to further demonstrate their belief and support in the business. Shares will be locked-up for a minimum of 180 days from issue date. All participants will be purchasing shares of Class A common stock directly from the Company."

17:50 EDT Athena Consumer Acquisition deadline to complete business combination extended - Athena Consumer Acquisition "announced that its board of directors has decided to extend the date by which Athena must consummate an initial business combination from September 22, 2023 for an additional month to October 22, 2023, and that its sponsor, Athena Consumer Acquisition Sponsor LLC deposited $60,000.00 into Athena's trust account in connection with this extension, the last of three potential one-month extensions of the Deadline Date available to Athena."

17:35 EDT 26 Capital Acquisition going into liquidation - 26 Capital Acquisition will be unable to complete an initial business combination within the time period required by its Certificate of Incorporation due to the Delaware Court of Chancery's decision denying 26 Capital's request for an order of specific performance in an action against certain of the parties to the Merger and Share Acquisition Agreement which 26 Capital entered into on October 15, 2021. Accordingly, the final $275K monthly installment to extend the Combination Period until October 20, 2023 will not be deposited into 26 Capital's trust account and instead, 26 Capital intends to liquidate the Trust Account on September 21. 26 Capital intends to pursue all available remedies against the UEC Parties, including damages. 26 Capital will redeem all of the outstanding shares of common stock included in the units issued to public stockholders in its initial public offering at a per-share redemption price of approximately $10.95. As of the close of business on or about September 25, the Public Shares will be deemed cancelled and stockholders will have the right to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after September 28. 26 Capital's sponsor has agreed to waive its redemption rights with respect to its founder shares. There will be no redemption rights or liquidating distributions with respect to 26 Capital's warrants, which will expire. 26 Capital expects that Nasdaq will file a Form 25 with the SEC to delist 26 Capital's securities.

17:08 EDT ProKidney investor Chamath Palihapitiya sells $9.3M in common stock - In a regulatory filing, ProKidney disclosed that its investor Chamath Palihapitiya sold 1.7M shares of common stock on September 19th in a total transaction size of $9.3M. Shares of ProKidney are down 3.5% afterhours at $4.20.

17:00 EDT 3D Systems CFO Michael Turner to step down - 3D Systems "announced that Michael Turner is stepping down as the company's CFO, effective October 15, 2023, to accept a new career opportunity. Andrew Johnson, 3D Systems' executive vice president, chief corporate development officer, and chief legal officer, has been appointed interim CFO, effective October 16. The company has initiated an executive search to identify a permanent finance leader."

16:57 EDT Scholastic falls 12% to $34.15 after reporting Q1 results

16:49 EDT BorgWarner says initial impact of UAW strikes on BorgWarner's sales 'modest' - In a regulatory 8-K filing, the company states: "On its second quarter 2023 earnings call, BorgWarner indicated that its aggregate sales to Ford, Stellantis, and General Motors in North America were expected to be just under $250 million per month on average during 2023. Given that the initial United Auto Workers strikes against these North American customers are focused on select final assembly plants, the impact of the initial strikes on BorgWarner's sales is currently expected to be relatively modest. However, to the extent the strikes continue for several weeks or expand to impact other customer plants, including those customers' engine and transmission plants, the impact on BorgWarner's sales will be larger. The Company does not intend to provide additional updates on this subject until its third quarter earnings call on November 2, 2023."

16:37 EDT Ondas promotes Yishay Curelaru to CFO - Ondas Holdings announced that Yishay Curelaru has been promoted to Chief Financial Officer, CFO , Treasurer and Secretary. Mr. Curelaru will report directly to Eric Brock, Ondas' Chief Executive Officer. In addition to his responsibilities at Ondas Holdings, Mr. Curelaru will continue to serve as CFO of Ondas' wholly owned subsidiary, Airobotics , and lead the financial management of the Ondas Autonomous Systems OASbusiness unit."I am pleased to have Yishay undertake this expanded role within Ondas Holdings," said Mr. Brock. "He brings extensive operating and financial experience to the company and has demonstrated exceptional performance and leadership in his operational, financial, and accounting roles at Ondas Autonomous Systems.

16:34 EDT 5E Advanced Metals gets EPA authorization to conduct step-rate testing - 5E Advanced Materials announced that it has received authorization from the Environmental Protection Agency to inject water, which initiates Step-Rate Testing, a condition under the Company's underground injection control UIC permit required to complete the final tests of injection-recovery wells. This approval to progress under the terms of the Company's existing permit marks a meaningful step towards conducting full boric acid and lithium carbonate extraction operations. Crucially, receipt of approval to conduct the Step-Rate Test to inject water marks significant advancement of the Company's goal of becoming the primary local U.S. provider of boron solutions, and a leading global producer of boron and boron-advanced derivatives. This decision comes after transparent communication with the EPA to ensure all conditions are met to receive authorization to inject water. ..."We are thrilled to announce our receipt of authorization to begin Step-Rate Testing, allowing 5E to advance through the final stages of preparing the wellfield and its ore body before commencing commercial operations, bringing 5E closer to being the first commercial scale Boric Acid production project in decades," said Chris Knight, VP of Operations at 5E Advanced Materials."

16:30 EDT Faraday Future names Matthias Aydt global CEO - Faraday Future Intelligent Electric announced the company's Board of Directors has appointed long term FF executive Matthias Aydt, Global CEO of Faraday Future, effective September 29, 2023. Also effective September 29, 2023, current Global CEO Xuefeng Chen will resume his prior position as FF China CEO, based in China and will take a new role as FF's EVP of Global Industrialization. "FF is currently focusing on ramping up FF91 production and beginning to generate revenue, improvement of product and technology capabilities and the development of next-generation products including AI developments," said Mr. Aydt. "I'm very excited for the new Global CEO role, and I'm confident that it will allow me to highlight my experience in product technology, research, and development for luxury car brands at global, world-class car companies and will provide tremendous value and leadership to FF."

16:23 EDT PNM Resources announces settlement agreement in San Juan coal plant case - PNM Resources reported that the New Mexico Public Regulation Commission - NMPRC - approved the unanimous settlement agreement reached by Public Service Company of New Mexico - PNM -, a wholly-owned subsidiary of PNM Resources, and parties in the case resolving all remaining steps involved in the retirement of the San Juan coal plant under New Mexico's Energy Transition Act. These steps include bill credits issued to customers and the issuance of lower-cost securitization bonds to fund the energy transition. Under the terms of the agreement, $115M in rate credits will be provided to customers over a one-year period. In addition, customers will be protected from rising interest rates if the weighted-average rate on the securitization bonds exceeds 5.5%.

16:18 EDT Bally's announces two new executive appointments - Bally's appointed Don Westcott as SVP, Global Chief Compliance Officer, and Tammi Barlow as Inaugural VP of Global Responsibility and Social Impact. Don Westcott has more than 25 years of experience within the financial technology and gaming industries. Most recently, he served as the Global Head of Compliance for Nuvei, an international payment service provider. Prior to that, he served in Vice President and Director roles with Fortune 500 companies Fiserv and First Data. He started his professional career within the gaming industry, including leadership roles with, among other enterprises, Caesars Entertainment, Osage Casinos, and the Isle of Capri Casinos. Prior to joining Bally's, Tammi Barlow led the development and execution of Rush Street Interactive's corporate social responsibility strategy. She is the previous co-chairwoman and is now a committee member of the Diversity, Equity, and Inclusion Committee for Global Gaming Women, and is currently Chairwoman of the Responsible Gaming Committee for the National Council on Problem Gambling, a Board member of the Massachusetts Council on Gaming and Health, and a committee member of African Americans in Gaming.

16:16 EDT Kidpik granted 180-day extension to meet Nasdaq bid price requirement - Kidpik Corp. announced that the company received written notification from the Listing Qualification Department of The Nasdaq Stock Market LLC granting the company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company now has until March 18, 2024 to meet the requirement. The company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rule 5550(a)(2) on March 22, 2023, and was given until September 18, 2023, to regain compliance. At any time during the additional 180-day extension, if the bid price of the company's common stock closes at, or above, $1.00 per share for a minimum of ten consecutive business days, the Nasdaq staff will provide the company with a written confirmation of compliance and the matter will be closed.

16:14 EDT LPL: Total client cash balances August-end $48.28B down $0.6B from July- end - LPL Financial released its monthly activity report for August 2023. Total advisory and brokerage assets at the end of August were $1.27T a decrease of $7.1B, or 0.6%, compared to the end of July 2023.Total net new assets for August were $13.1B, translating to a 12.3% annualized growth rate. Total net new advisory assets were $8.3B, translating to a 14.6% annualized growth rate. Total client cash balances at the end of August were $48.2B, a decrease of $0.6B compared to the end of July 2023. Net buying in August was $12.7B.

16:10 EDT Puma Biotechnology receives FDA orphan drug designation for Alisertib - Puma Biotechnology announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A, for the treatment of patients with small cell lung cancer. SCLC is an aggressive form of lung cancer with a poor prognosis, and with limited treatment options for patients whose cancer has progressed on or after platinum-based chemotherapy. "Obtaining Orphan Drug Designation from the FDA signifies our continued progress and commitment to the development of alisertib for the treatment of small cell lung cancer," said Alan H. Auerbach, Chief Executive Officer, President and Founder of Puma. "There is an urgent need for new treatments for patients with small cell lung cancer, and we look forward to the initiation of our Phase II trial (Study PUMA-ALI-4201) of alisertib in small cell lung cancer."

16:06 EDT Masco names Richard Westenberg as new CFO - Masco "announced the election of Richard Westenberg as Vice President, CFO, effective October 16, 2023. Mr. Westenberg is a seasoned executive who brings to Masco over 25 years of experience, including nearly 15 years leading global finance organizations. Most recently, he served as Vice President and Chief Financial Officer of General Motors North America, overseeing the financial management and financial performance of this approximately $125 billion segment, and leading a team across the U.S., Canada and Mexico."

16:03 EDT Texas Instruments increases dividend 5% to $1.30 per share - Texas Instruments will raise its quarterly cash dividend 5%, from $1.24 per share to $1.30, or $5.20 annualized. The higher dividend will be payable November 14 to stockholders of record on October 31, contingent upon formal declaration by the board of directors at its regular meeting in October.

15:32 EDT Mitek Systems enters into strategic partnership with Equifax - Mitek Systems (MITK) "announced a strategic partnership with Equifax (EFX). The agreement will add Mitek's biometric-based identity verification and liveness detection technology to Equifax's digital identity software, further strengthening Equifax's ability to help companies prevent identity fraud. Credit card fraud is proven to be the top form of identity fraud with more than 400,000 reports in the past year. To combat emerging fraud threats, Equifax will leverage Mitek's artificial intelligence-powered identity verification technology with its own fraud data solutions."

15:05 EDT Scopia reports 5.1% stake in Harmonic, says intends to continue to engage - Scopia Capital Management disclosed a 5.1% stake in Harmonic and stated in a regulatory filing: "The shares held by the Investment Vehicles were purchased based on the Reporting Persons' belief that the shares, when purchased, were undervalued and represented an attractive investment opportunity... The Reporting Persons have engaged, and intend to continue to engage, in communications with the issuer's Board of Directors and management team regarding opportunities to enhance stockholder value."

14:50 EDT Ace Global Business Acquisition announces extension of combination period - Ace Global Business Acquisition, a special purpose acquisition company, announced that at its special meeting of shareholders on September 19, the company's shareholders voted in favor of the proposal to amend and restate its amended and restated memorandum and articles of association, giving the company the right to extend the date by which the company has to complete a business combination a total of six times for an additional one month each time from October 8, 2023 to April 8, 2024.

13:59 EDT Skechers CFO says back half 'a little bit softer' than anticipated in wholesale - Asked during the Wells Fargo Consumer Conference how the company is thinking about wholesale into the second half, Skechers CFO John Vandemore replied, according to a transcript of the event: "Well, we haven't really adjusted our view on the full year, just mathematically, what that meant because the second quarter was a little bit better than expected, we've flowed through some of that to the back half of the year. That makes the back half look a little weaker than maybe we had originally expected, but that it really is just math to hold the year constant because, again, we haven't seen that reorder come through yet or massive collapse. If we do start to see that there's absolutely opportunity to outperform, and we'd be open to have that happen, but we haven't seen it yet in the years close pretty fast. So I would say in the back half right now, it's a little bit softer than we originally indicated, but really that's the whole the whole year view consistent with how we started. And again, what we're hoping for is that some of those green shoots that we've seen in the business start to materialize in the form of either pulled forward orders or incremental orders because that's what we'll ultimately get the product into their hands and then into the consumer's hands."

13:11 EDT Microsoft confirms Copilot AI to begin rolling out September 26 - Microsoft said in a blog post: "We are entering a new era of AI, one that is fundamentally changing how we relate to and benefit from technology. With the convergence of chat interfaces and large language models you can now ask for what you want in natural language and the technology is smart enough to answer, create it or take action. At Microsoft, we think about this as having a copilot to help navigate any task. We have been building AI-powered copilots into our most used and loved products - making coding more efficient with GitHub, transforming productivity at work with Microsoft 365, redefining search with Bing and Edge and delivering contextual value that works across your apps and PC with Windows. Today we take the next step to unify these capabilities into a single experience we call Microsoft Copilot, your everyday AI companion. Copilot will uniquely incorporate the context and intelligence of the web, your work data and what you are doing in the moment on your PC to provide better assistance - with your privacy and security at the forefront. It will be a simple and seamless experience, available in Windows 11, Microsoft 365, and in our web browser with Edge and Bing. It will work as an app or reveal itself when you need it with a right click. We will continue to add capabilities and connections to Copilot across to our most-used applications over time in service of our vision to have one experience that works across your whole life. Copilot will begin to roll out in its early form as part of our free update to Windows 11, starting Sept. 26 - and across Bing, Edge, and Microsoft 365 Copilot this fall." Reference Link

12:12 EDT Ubisoft confirms working on 'Tom Clancy's The Division 3' game - Ubisoft's Massive Entertainment announced that Julian Gerighty has been appointed Executive Producer for the "Tom Clancy's The Division" brand. Julian will oversee all games and products, including "Tom Clancy's The Division 3," led by Massive Entertainment who is actively building a team for the game. Reference Link

12:00 EDT Endeavor Group falls -8.7% - Endeavor Group is down -8.7%, or -$1.94 to $20.43.

12:00 EDT Cato Corp. rises 6.2% - Cato Corp. is up 6.2%, or 46c to $7.82.

12:00 EDT Graf Acquisition IV rises 10.9% - Graf Acquisition IV is up 10.9%, or $1.06 to $10.80.

11:44 EDT FactSet sees 'weaker' 1H24, 'stronger' 2H, driven by improved client sentiment - Comments taken from Q4 earnings conference call.

11:32 EDT PolyPid trading resumes

11:25 EDT Oneok shareholders, Magellan unitholders approve merger - Oneok (OKE) and Magellan Midstream Partners (MMP) announced that, at their respective special meetings, Oneok shareholders and Magellan unitholders approved the previously announced merger. The merger remains subject to satisfaction of other customary closing conditions and is anticipated to close before market on Monday, September 25, with Magellan common units expected to cease trading on the New York Stock Exchange at the close of business on Friday, September 22. As previously announced, upon completion of the transaction, Magellan unitholders will receive $25.00 in cash and 0.667 shares of Oneok common stock for each outstanding Magellan common unit they own immediately prior to the effective time of the transaction.

11:04 EDT Keysight, Synopsys partner for IoT device cybersecurity - Keysight Technologies (KEYS) and Synopsys (SNPS) are partnering to provide internet of things device makers with a comprehensive cybersecurity assessment solution to ensure consumers are protected when devices are shipped to market. Under the arrangement, the Synopsys Defensics fuzzing tool will be embedded as an option into the Keysight IoT Security Assessment solution.

10:10 EDT Reata stockholders approve merger transaction with Biogen - Reata Pharmaceuticals (RETA) announced that at a special meeting held today, preliminary results indicate that the stockholders of the company voted to approve the company's previously announced acquisition by Biogen (BIIB). The expected closing date of the merger is September 26, the company stated. "We are pleased to announce that our stockholders have approved our acquisition by Biogen. This marks a significant milestone in Reata's journey, and I thank our stockholders for their strong support. We believe the acquisition by Biogen will significantly advance Reata's vision of developing and delivering novel therapies to patients with rare diseases," said Warren Huff, Chairman and CEO at Reata.

10:03 EDT Studio City falls -7.1% - Studio City is down -7.1%, or -45c to $5.90.

10:03 EDT Endeavor Group falls -8.4% - Endeavor Group is down -8.4%, or -$1.87 to $20.50.

10:03 EDT PBF Energy rises 5.7% - PBF Energy is up 5.7%, or $3.03 to $55.93.

10:00 EDT FedEx rises 5.9% - FedEx is up 5.9%, or $14.84 to $265.36.

09:51 EDT Endeavor Group falls -6.8% - Endeavor Group is down -6.8%, or -$1.53 to $20.84.

09:51 EDT Direxion Daily Junior Gold Miners Index Bear 3x Shares rises 5.3% - Direxion Daily Junior Gold Miners Index Bear 3x Shares is up 5.3%, or 37c to $7.30.

09:47 EDT FedEx rises 5.8% - FedEx is up 5.8%, or $14.55 to $265.07.

09:37 EDT TradeUP Acquisition Corp trading resumes

09:32 EDT Murphy Canyon Acquisition Corp trading halted, volatility trading pause

09:32 EDT Foresight Autonomous partners with electric vehicle manufacturer - Foresight Autonomous Holdings announced the signing of a multi-phase cooperation agreement with a leading global electric vehicle Chinese original equipment manufacturer, specializing in EVs, rechargeable batteries and related products. The first phase of the agreement consists of a proof of concept project to evaluate Foresight's 3D perception capabilities, including high resolution point cloud, object detection and disparity map, for possible enhancement of the OEM's current automotive vision solution. Upon successful completion of the POC project, the parties intend to negotiate a definitive commercial agreement for the joint development, integration and commercialization of Foresight's technology into the OEM's automotive vision systems. Furthermore, the OEM will introduce Foresight's technology to its subsidiaries as well as customers and partners, presenting Foresight as a business partner and facilitating relationships between Foresight and the OEM's partners.

09:24 EDT Instructure partners with K16 Solutions for Canvas archiving solution - Instructure announced an exclusive partnership with K16 Solutions, a provider of content and data migration and integration, extending access to an archiving solution to all Canvas customers. The solution, Canvas Archiving Powered by K16 Solutions, is available immediately to Canvas customers worldwide. Canvas Archiving Powered by K16 Solutions gives Canvas users a way to control access to sensitive data and back up all student and course data with the click of a button.

09:19 EDT Trio Petroleum provides update on testing of HV-1 Discovery Well - Trio Petroleum provided an update on the testing of the HV-1 discovery well at the Company's South Salinas Project. The Brown Zone in the HV-1 well was perforated on September 7 with 350 feet of perforations across a gross interval from 5,465 to 5,850 feet measured depth and then acidized for borehole clean-up. The well was then tested by swabbing for seven days during the September 8-18 timeframe. A pumping unit is now being installed at the HV-1 well for further testing of the Brown Zone and temporary tanks and other facilities are also being installed at the well site. Results of pumping will be announced when available. The Brown Zone in the HV-1 well is mechanically isolated from the deeper Mid-Monterey Clay zone that we previously tested with results previously announced. Swab testing to-date suggests that the Brown Zone and the Mid-Monterey Clay collectively, if commingled, might deliver approximately 145 barrels of oil per day, with potentially significantly higher oil production rates when the well is on pump. Trio's CEO, Frank Ingriselli, stated: "We continue to be encouraged by the preliminary test results at the HV-1 well. We should get a much better understanding of the potential rates of oil and gas production at the well by having it on pump. Though our original primary objective was the Yellow Zone, also known as the Yellow Chert, which we still believe will be the most prolific producing zone of the structure, we have been very encouraged by the results in the Brown Zone and the Mid-Monterey clay. Given the greater than expected positive results, we may decide to initially produce from the Brown Zone, or to produce from the Brown Zone and the Mid-Monterey clay commingled for the foreseeable future and wait moving up-hole to the top of the anticline to test and produce from our primary objective - the Yellow Zone. We will continue to announce results as additional information becomes available."

09:18 EDT Ubuy selects Nuvei to enhance customer checkout experience - Nuvei Corporation has been selected by Ubuy to enhance its customer checkout experience. Ubuy is leveraging Nuvei's global reach, local payments market expertise, and extensive suite of alternative payment methods, to enter new markets and offer its customers a diverse selection of payment options. Nuvei currently offers its customers access to 634 APMs, all available through a single integration. Online businesses can tailor each respective end market via the most relevant payment methods for that region to optimize the consumer checkout experience.

09:17 EDT Lexaria Bioscience to evaluate impact of DehydraTECH on GLP-1 drugs - Lexaria Bioscience announces its intention to launch new human and animal studies to examine DehydraTECH-processed glucagon-like peptide-1 drugs such as, but not limited to, semaglutide sold under Novo Nordisk's brand names Ozempic, Wegovy and Rybelsus, for purposes of improved bioavailability, cost-effectiveness, tolerability, weight loss potential, management of diabetes and other health conditions. Through these studies, Lexaria hopes to achieve superior pharmacokinetic performance using DehydraTECH-powered GLP-1 drugs which could enable drug delivery via oral capsule at lower costs than current injectables, with reduced side effects and enhanced health benefits. This is a significant expansion of Lexaria's ongoing and planned diabetes study program to examine its patented DehydraTECH-CBD for diabetes control in humans. The Company now intends to evaluate this alongside and together with DehydraTECH-processed GLP-1 agents. Program design has already commenced, and initial study work will begin as soon as possible.

09:13 EDT Rupert Murdoch stepping down as chairman of News Corp. and Fox - Fox Corporation (FOXA, FOX) and News Corporation (NWS, NWSA) announced that Rupert Murdoch is stepping down as chairman of each board effective as of the upcoming annual general Meeting of shareholders of each company in mid-November. Murdoch will be appointed Chairman Emeritus of each company. Following the annual meetings, Lachlan Murdoch will become sole Chair of News Corp. and continue as Executive Chair and Chief Executive Officer of Fox Corporation. Lachlan Murdoch said, "On behalf of the FOX and News Corp boards of directors, leadership teams, and all the shareholders who have benefited from his hard work, I congratulate my father on his remarkable 70-year career. We thank him for his vision, his pioneering spirit, his steadfast determination, and the enduring legacy he leaves to the companies he founded and countless people he has impacted. We are grateful that he will serve as Chairman Emeritus and know he will continue to provide valued counsel to both companies."

09:10 EDT News Corp. says Rupert Murdoch stepping down as chairman

09:08 EDT Rogers Communications investing in wildfire detection, prevention technology - Rogers Communications is investing in wildfire detection and prevention technology as part of the company's commitment to keeping Canadians and first responders safe. The company will use its national network and technology partnerships to help combat climate change-related events in communities across the country. Rogers is using satellite-connected sensors, with SpaceX's low-bandwidth Swarm service, to better predict wildfires in remote areas of British Columbia without wireless networks. Rogers is introducing Pano AI cameras on the Rogers 5G network that detect smoke up to a 20-kilometre range. The AI cameras will be located on wireless towers in the province near Fort St. James, Smithers and Chetwynd. The company is also donating satellite phones to the British Columbia Search and Rescue Association to support first responders.

09:05 EDT Krystal Biotech announces FDA clearance of IND application for KB408 - Krystal Biotech announced that the U.S. Food and Drug Administration, FDA, cleared the Investigational New Drug Application, IND, for KB408 for the treatment of alpha-1 antitrypsin deficiency, AATD. "We are excited to advance KB408, our investigational gene therapy for patients with alpha-1 antitrypsin deficiency, into the clinic in our Serpentine-1 study," said Hubert Chen, M.D., Senior Vice President of Clinical Development at Krystal Biotech. Dr. Chen continued, "This IND acceptance represents an important milestone for us as we work to address a serious lung disease with limited treatment options, and also allows us to demonstrate the potential of our platform to deliver genes repeatedly to epithelial cells of the lung."

09:05 EDT Northwest Bancshares CFO/COO William Harvey, Jr. to retire December 31, 2024 - Northwest Bancshares and Northwest Bank announced that they have entered into a retirement agreement and a consulting agreement pursuant to which Senior Executive Vice President, CFO and COO William Harvey, Jr. will transition from his current roles in 2024. Harvey will retire from the company and Northwest Bank and their associated boards on December 31, 2024 but remain with the organization as a consultant through December 31, 2025. His continued employment and consulting periods are designed to assist with a seamless transition of duties. The company and Northwest Bank have initiated a search to hire an individual who will serve as Harvey's replacement as CFO. The search will consider both internal and external candidates. The company estimates that the search will take four to six months to complete.

09:04 EDT Gurnet Point, Novo complete acquisition of Paratek Pharmaceuticals - Gurnet Point Capital and Novo Holdings announced the completion of their acquisition of Paratek Pharmaceuticals. "Today's completion of the acquisition of Paratek by Gurnet Point and Novo Holdings represents the beginning of a new chapter in our Company's history," said Evan Loh, M.D., Chief Executive Officer at Paratek. "We look forward to drawing upon the extensive experience of both Gurnet Point and Novo Holdings to provide lifesaving, transformative therapies to patients." The consideration paid to stockholders in the transaction was $2.15 per share in cash, plus a Contingent Value Right of $0.85 per share payable upon the achievement of $320 million in U.S. NUZYRA net sales in any calendar year ending on or prior to December 31, 2026. Under the terms of the merger agreement, Gurnet Point and Novo Holdings acquired all outstanding shares of Paratek for approximately $462 million, including the assumption of debt and assuming full payment of a CVR. Stockholders approved the merger agreement proposal at Paratek's special meeting of stockholders on September 18, 2023 in connection with the previously announced definitive agreement between the Company, Gurnet Point and Novo Holdings. Paratek will be delisted from NASDAQ Global Exchange.

09:04 EDT Texas Capital appoints Amos McDonald as head of business banking - Texas Capital Bancshares announced that the firm has appointed Amos McDonald as head of Business Banking, effective immediately. McDonald is based in The Woodlands, Texas, and is responsible for setting and driving production goals within the firm's Business Banking division and leading a seasoned team of bankers. He reports to Texas Capital Managing Director and Head of Commercial Banking Jay Clingman, who is responsible for the firm's commercial strategy and expanding its commercial client base. McDonald has been with Texas Capital for two years, previously serving as Business Banking group manager for The Woodlands market.

09:02 EDT STMicroelectronics releases software to connect IoT devices to Microsoft IoT Hub - STMicroelectronics has released software that simplifies connecting IoT devices built using the latest high-performing STM32H5 microcontrollers to Microsoft Azure IoT Hub. ST's STM32Cube expansion package, named X-CUBE-AZURE-H5, consists of a set of libraries and application examples for high-performance microcontrollers of the STM32H5 series, acting as end devices. The sample application shows secure device-to-cloud connectivity with Azure IoT Hub, including network configuration and data publishing. The application handles Azure messages, methods, and twin update commands. This solution also leverages ST's embedded security software, Secure Manager, to connect securely the STM32H5 to Microsoft Azure cloud.

09:00 EDT Rubicon Technologies enters five-year smart city partnership with Phoenix - Rubicon Technologies announced that it has entered into a five-year smart city partnership with the City of Phoenix, Arizona to digitize and improve efficiencies across the City's solid waste collection operation. The agreement will put Rubicon's smart city software at the heart of Phoenix's Public Works Department, providing waste and recycling collection to more than 418,000 locations weekly. Rubicon will help the City digitize its solid waste collection operation, transitioning from largely manual and paper-based processes to using tablets running Rubicon's software in Phoenix's solid waste and recycling fleet of more than 300 vehicles. The City will use Rubicon's technology to streamline collection services, and reduce missed pickups and unnecessary go-backs. With digital routes, the City will be able to closely monitor route performance, identify areas where waste and recycling services can be improved, and make data-driven decisions to enhance route efficiency and better serve the Phoenix community.

08:54 EDT A2Z Smart Technologies forms strategic advisory board - A2Z Smart Technologies announced the formation of the Cust2Mate advisory board, alongside the appointment of Steve Robinson as a member of the advisory board, to help guide strategic initiatives and drive company growth. Steve brings a deep understanding of the retail industry from his roles at Walmart and Starbucks. A2Z is leveraging its advisory board to help scale and expand its Cust2Mate solution, an AI and computer vision-equipped smart shopping cart. Cust2Mate's transition to a global software platform provider is strengthened by successful deployments with leading retailers, solidifying A2Z Cust2mate's position as an industry pioneer with its advisory board's strategic guidance.

08:52 EDT SKYX Platforms provides business update including issuance of five patents - SKYX Platforms announced a business update, including the issuance of five new utility patents in the U.S. and international markets including Canada, Mexico and Hong Kong for its related smart plug-and-play products including a ceiling fan with a heater and recessed light. The five additional patents announced today are in addition to the three issued patents that were announced two weeks ago - which brings the Company's intellectual property portfolio to a total of 77 issued and pending patents, 23 of which are issued patents covering SKYX's advanced and smart technologies. Business Update: The Company continues to enhance the market penetration of its ceiling outlet receptacle as well as smart and standard plug & play ceiling products. SKYX files for a mandatory safety standardization with the National Electrical Code for its ceiling outlet receptacle for ceilings in homes and buildings. SKYX's code team is led by Mark Earley, former head of the National Electrical Code, and Eric Jacobson, former President and CEO of the American Lighting Association. In past 30 years, both Mark Early and Eric Jacobson led instrumental safety code changes in the electrical and lighting industries. SKYX's code team has submitted significant supporting data regarding hazardous incidents that occur due to electrical wire installations including fires, ladder falls, electrocutions, injuries, and deaths caused due to hazardous wire installations. After years of rigorous standardization progress, SKYX's code team and management strongly believe that it has met the necessary safety conditions and has significant supporting data for a compelling case for its ceiling outlet receptacle to become a mandatory safety standardization for ceilings in homes and buildings. In a market of hundreds of millions of installations, a mandatory safety standardization of SKYX's ceiling outlet would eliminate the need to touch hazardous wires in the ceiling during installation. The last major mandatory safety code change for homes and buildings by the National Electrical Code was the GFCI, the safety outlet receptacle for bathrooms and kitchens. The Company's cash, cash equivalents, restricted cash, and investments available for sale totaled $23.7 million as of June 30, 2023. The Company's e-commerce business including over 60 websites, enhances SKYX's cash flow and marketing as well as provides distribution to both professional and retail markets. SKYX signs an agreement with world leading product material supply company to architects, builders, and designers - Material Bank - with over 100,000 customers.

08:49 EDT Sigma Additive Solutions announces 1-for-20 reverse stock split - Sigma Additive Solutions will effect a 1-for-20 reverse stock split of its outstanding common stock to seek to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2) by the October 8, 2023 deadline for doing so. Regaining compliance is also expected to facilitate the transactions contemplated by Sigma's recently announced non-binding letters of intent to acquire NextTrip Holdings, Inc. and sell certain quality assurance software assets. The Company's common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis when the market opens on Friday, September 22, 2023, and will continue to trade under the symbol "SASI." The new CUSIP number for the common stock following the reverse stock split will be 826598609. The number of shares of common stock that Sigma Additive Solutions is authorized to issue will correspondingly decrease from 24,000,000 shares at present to 1,200,000 shares.

08:48 EDT ReShape Lifesciences signs exclusive license agreement with Biorad Medisys - ReShape Lifesciences announced the signing of an exclusive, royalty-bearing license agreement with Biorad Medysis, to manufacture, commercialize and distribute the Obalon Gastric Balloon System in India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka, and the Maldives. Based in Mumbai, India, The license agreement provides $200,000 in upfront payments from Biorad to ReShape and ongoing license payments of 4% on gross sales of the Obalon Balloon System in the territories. "This exclusive agreement with Biorad represents the first step towards reintroducing our patented Obalon Balloon System technology to the global marketplace," stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. "We believe that Biorad, with decades of experience manufacturing and distributing medical devices in the vast South Asia market, potentially reaching approximately 20% to 25% of the world's population, is an ideal partner to expand the reach of ReShape's Obalon technology. Our non-surgical, minimally invasive, Obalon System was the first swallowable, gas filled balloon system approved by the U.S. Food and Drug Administration, around which we continue to build a strong intellectual property portfolio. We look forward to a fruitful partnership with Biorad, which we expect will lay the groundwork to catalyze the successful relaunch and joint commercialization of the balloon system in markets world-wide."

08:47 EDT 3D Systems issues letter to shareholders of Stratasys - 3D Systems (DDD) issued the following public letter to shareholders of Stratasys (SSYS) after leading independent proxy advisor, Institutional Shareholder Services, recommended that Stratasys shareholders vote AGAINST Stratasys' planned acquisition of Desktop Metal (DM) ahead of its September 28, 2023 Extraordinary General Meeting of Shareholders to vote on the Desktop Metal transaction. ISS discussed its recommendation in a detailed, 9-page analysis that concluded: "It is not clear that creates value for SSYS shareholders. DDD's alternative offer to acquire, by contrast, presents a more convincing route to value creation for SSYS shareholders." The full text of 3D Systems' letter is as follows: "Stratasys Shareholders, You have a critical decision to make on September 28th about the future of Stratasys: 1. Vote FOR the planned all-stock merger with Desktop Metal, a transaction that would massively dilute Stratasys shareholders only to rescue an amalgamation of deteriorating additive manufacturing businesses rapidly cobbled together in 2021. Or 2. Vote AGAINST the Desktop Metal transaction to send a clear message to the Stratasys Board of Directors to accept the superior cash and stock offer from 3D Systems. The transaction with 3D Systems would provide Stratasys shareholders with approximately $509 million of upfront cash consideration and ownership of 46% of the combined company, featuring a scaled platform with industry-leading revenues, highly attractive gross margins, positive EBITDA and attractive upside exposure to its high-growth regenerative medicine platform."

08:44 EDT Arcimoto enters into contract manufacturing agreement with MOBIUS.energy - Arcimoto announced it has entered into a contract manufacturing agreement with MOBIUS.energy Corporation, a cutting-edge energy technology company, to enhance the charging capabilities of its electric vehicles, develop MUV based mobile charging solutions and build ultra lightweight aviation batteries. This collaboration marks a significant milestone in the electric vehicle industry, paving the way for faster, more efficient charging and expanding Arcimoto's reach into the charging market. Under the terms of the contract agreement, Arcimoto will manufacture MOBIUS packs for their current and future customers. The MOBIUS packs are set to radically transform EV charging with rapid charging capabilities. Upon the successful launch and testing of the prototypes, Arcimoto plans to integrate MOBIUS technology into its production vehicles for mobile charging and achieve charging times of less than ten minutes, from zero to full charge. "Our collaboration with MOBIUS is a game-changer for the electric vehicle industry," said Chris Dawson, chief executive officer at Arcimoto. "By leveraging MOBIUS' cutting-edge energy technology, we are not only revolutionizing EV charging but also facilitating the electrification of the aviation industry. We are excited to embark on this journey with MOBIUS and deliver unparalleled value to our customers."

08:43 EDT Live Ventures acquires Harris Flooring Group brands from Q.E.P. - Live Ventures announced that its subsidiary Marquis Industries has acquired the Harris Flooring Group brands from Q.E.P. The Harris Flooring Group comprises four major flooring brands: Harris, Kraus, Naturally Aged Flooring, and Heritage Mill Wood Flooring. On September 20, 2023, Marquis Industries acquired the Harris Flooring Group brands, inventory, and book of business and intends to retain substantially all Harris Flooring Group employees and sales representatives. The transaction, valued at approximately $10M, is set to double Marquis Industries' salesforce and is expected to significantly impact Marquis Industries and its operations while contributing substantial revenues. "As part of the growth strategy for our flooring manufacturing segment, we are excited to announce the acquisition of the Harris Flooring Group by our subsidiary, Marquis Industries," said Jon Isaac, President and Chief Executive Officer of Live Ventures. "We believe the acquisition will be very synergistic and add significant revenues to Marquis Industries."

08:42 EDT Mosaic comments on CIT countervailing duty ruling - The Mosaic Company commented on a ruling from the U.S. Court of International Trade, which remanded the U.S. International Trade Commission's injury finding back to the ITC for reconsideration. CIT appeals are common in trade remedy cases, and in most cases remanded to the ITC for reconsideration, the original finding of injury is affirmed. In OCP S.A. et al. v. United States, the CIT remanded on one specific factual issue out of many that the ITC relied upon. Neither the ITC nor the U.S. Department of Commerce have thus far changed anything from their earlier determinations, and as a result, countervailing duties on phosphate fertilizers remain in effect with no changes to the rates applied at the border. "The basic facts that led to countervailing duties on imports from Morocco and Russia remain unchanged," said Joc O'Rourke, Chief Executive Officer. "We will continue to participate actively before the agencies and the courts to defend the original findings."

08:41 EDT Biodexa to present update on recruitment, patients in Phase 1 study of MTX-110 - Biodexa Pharmaceuticals announces that it will be presenting an update on the recruitment and treatment of patients in the ongoing Phase 1 study of MTX-110 in patients with recurrent glioblastoma during a poster session on 22 September 2023, at the 2023 annual EANO meeting in Rotterdam, the Netherlands. As of the time of this announcement, three patients have been dosed in the first cohort of the study. No dose-limiting toxicities have been observed at any dose level; and all study-related, non-surgical adverse events were grade 1 or 2 and correlated with the location of the lesion being treated. Patient 1 has received 13 treatment cycles over 19 weeks of study treatment period, whereas patient 2 received 10 cycles over 13 weeks of study treatment period; patient 3 has been recently enrolled and continues to receive treatment.

08:39 EDT Hologic, Bayer team to bring contrast-enhanced mammography package to facilities - Hologic (HOLX) and Bayer (BAYRY) announced an international partnership to deliver contrast-enhanced mammography or CEM, solutions to improve the detection of breast cancer for women in multiple countries across the European, Canadian and Asia Pacific regions. The partnership brings together the companies' leading technologies to enable the administration of contrast media during a mammography examination. With the new agreement, Bayer and Hologic aim to optimally support radiologists and their teams' needs by providing a comprehensive product package along with the hands-on training needed to effectively implement CEM into their facility's workflow. "Over the past several years, we've seen an increased interest in contrast-enhanced mammography as an additional diagnostic modality. Our partnership with Bayer will enable clinicians around the world to offer CEM as part of the breast cancer diagnostic workflow," said Tanja Brycker, Vice President, Strategic Development, Breast and Skeletal Health and GYN Solutions at Hologic. "As one of the world leaders in mammography and women's health, we are committed to enabling healthier lives everywhere, every day. By increasing access to additional breast imaging technology to women across the globe, our international partnership with Bayer is a compelling example of that commitment in action."

08:37 EDT Genprex receives ODD for Immunogene Therapy for treatment of SCLC - Genprex announces its placement in an editorial published by NetworkNewsWire. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex was granted FDA orphan drug designation, ODD, for its REQORSA immunogene therapy in development for the treatment of small cell lung cancer, SCLC.

08:36 EDT Lipella Pharma's hemorrhagic cystitis candidate shows efficacy in Phase 2 study - Lipella Pharmaceuticals announced that the results of its successful Phase 2a clinical trial have been the published in the peer-reviewed Journal of Urology and Nephrology. The article highlights the clinically meaningful efficacy and safety profile of Lipella's lead product candidate, LP-10 as a potential treatment for hemorrhagic cystitis. LP-10 has received Orphan Disease Designation from the US Food and Drug Administration (FDA) for the treatment of hemorrhagic cystitis, a potentially fatal disease with great unmet need and no currently approved drug treatment. Lipella is scheduled to have a Type-C meeting with FDA in Q4 and expects to initiate a Phase 2b clinical trial for LP-10 in January 2024. Pharmacokinetic analysis demonstrated a very short duration of systemic uptake and symptomatic improvements including: decreased hematuria, decreased cystoscopic bleeding, a reduced number of ulceration sites, and improved urinary symptoms.

08:35 EDT ProSomnus raises $10M to fuel growth, optimize operations - ProSomnus announced the completion of a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital, LLC. ProSomnus's Executive Chair, CEO, and CFO are also participating in the financing. A description of the terms of the offering can be found in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2023. The new capital will be leveraged to optimize the Company's core business operations and support its strategic growth initiatives, as the Company works to achieve cash flow breakeven. "The completion of this financing fortifies our balance sheet as we continue our mission to make precision oral appliance therapy the preferred first-line treatment for Obstructive Sleep Apnea," said Len Liptak, Co-Founder and CEO. "As we discussed on our second quarter call, the ProSomnus team is executing at a high level, having reported 48% revenue growth in the first half of 2023 and additional scientific data demonstrating the effectiveness of ProSomnus precision devices. We will leverage this new capital to fine-tune our operating model, as we work to reach cash flow breakeven while still delivering strong top line growth. This financing is a key step forward and I am more confident than ever in our ability to demonstrate the compelling efficacy and adherence of our devices compared to alternative therapies including CPAP and hypoglossal nerve stimulation."

08:33 EDT SuperCom secures new national program with the government of Finland - SuperCom announced it has secured a new national program with the government of Finland. This program includes the deployment of SuperCom's Domestic Violence Monitoring Solution, an integral component of its PureSecurity Electronic Monitoring Suite. This achievement follows a previously successful EM project launched earlier this year in collaboration with the Ministry of Justice of Finland, focused on EM solutions for incarcerated individuals and those on probation. The primary objective of this project is to empower Finnish authorities, safeguard victims, and proactively prevent domestic violence incidents, thereby enhancing the safety and well-being of Finnish citizens. SuperCom's innovative and proven technology and services play a critical role in achieving this objective. The project will consist of the following PureSecurity offerings: PureProtect, PureTrack, PureTag, and PureMonitor. Together, these solutions equip the Finnish authorities with near real-time information necessary to ensure the safety of victims and enforce court-mandated restrictions. Anticipated deployment and start of recurring revenue generation expected in the 4th quarter of 2023.

08:32 EDT Aviat Networks awarded over $50M in public safety orders - Aviat Networks has received orders totaling over $50M with two separate U.S. State governments for statewide public safety networks. These projects involve a mix of high-power microwave radios, high availability routers, and management software along with turnkey services for design, installation, support, and ongoing managed services. Aviat's Frequency Assurance Software will be incorporated into these statewide network upgrades to protect first responders from potential Wi-Fi 6e interference, along with Health Assurance Software to ensure reliable and robust communications throughout the networks.

08:31 EDT Canoo establishes agreement with the Pawnee Nation - Canoo Technologies announced that it has established an agreement with the Pawnee Nation, based in Pawnee, Oklahoma, to identify and nurture emerging business and job opportunities in Oklahoma's growing clean energy industry. "Our decision to locate our manufacturing in Oklahoma was driven in part by opportunities to work with tribal nations and others to further diversify local economies and to help create good jobs for working people in a dynamic emerging industry," says Tony Aquila, Chairman and CEO, Canoo. "Under this agreement, the Pawnee Nation and Canoo will work together to train workers and develop suppliers for Oklahoma's growing clean energy industry." The agreement between the Pawnee Nation and Canoo is focused on four areas, Aquila says. First, building workforce skills in zero-emission vehicles and other clean energy technologies. Second, developing qualified suppliers of parts and services needed for the zero-emission vehicle industry. Third, supporting STEM education by connecting Pawnee students to internships and employment opportunities in clean energy fields. And finally, the Pawnee Nation will place an initial order for Canoo vehicles that will be built in Oklahoma.

08:27 EDT Atreca announces departure of CFO Cross, agreement to terminate lease - Atreca announced that, as part of its ongoing efforts to lower operating expenses, the Company has entered into an agreement to terminate its lease agreement pertaining to the Company's headquarters in San Carlos, CA, which represented approximately $13M of annual expenditures. In addition, Herb Cross, Chief Financial Officer, will depart the Company on September 22, 2023, to pursue an external opportunity. Cross will continue to support the Company as a consultant through the first quarter of 2024. John Orwin, Chief Executive Officer of the Company, will assume the role of principal financial officer and Rick Ruiz, Vice President, Finance of the Company, will assume the role of principal accounting officer going forward. Under the terms of its amended lease agreement with Alexandria Real Estate Equities, Inc., Atreca will terminate its long-term lease entered into in July 2019 in exchange for aggregate consideration of approximately $5 million. Atreca will vacate the premises by November 30, 2023, and will be evaluating options for facilities sized to its current operational needs.

08:27 EDT Asante Gold appoints Malik Fasah as executive chairman - The Company is also pleased to report that Malik Easah has accepted the role of Executive Chairman. Mr. Easah was previously an Executive Director of the Company. Mr. Douglas MacQuarrie has stepped down from the Non-Executive Chairman role while remaining a non-executive Director of the Company. The Board thanks Mr. MacQuarrie for his service. The Company is also pleased to report that it has entered into an agreement with a strategic financial institution for the forward sale of gold which will provide $40 million of financing to the Company on a revolving basis over a two-year period. Under the Agreement, a subsidiary of the Company will deliver 4,000 ounces of refined gold per month to the Purchaser for 24 months, commencing in October 2023. As an advance deposit towards future gold deliveries, the Purchaser will pay the equivalent of $40 million in local currency to a subsidiary of the Company shortly after execution of the Agreement. Deliveries will be credited against the Deposit and funds will be re-advanced, at the Company's election, on each fifth monthly anniversary of execution of the Agreement. The Company continues to pursue other near-term, non-dilutive financing initiatives to support capital investments and working capital requirements.

08:26 EDT Asante Gold provides operations, corporate update - Asante Gold provides an update on its operations and corporate activities. The Bibiani process and mine facilities are operating on a 24 hour per day basis with throughput of approximately 3.0M tonnes per year. Completion of critical plant upgrades and other capital initiatives, as outlined below, are expected to enable material increases in throughput, gold recovery and production levels with a commensurate decrease in all-in sustaining costs per ounce in Q4 2023. The Company continues to advance near-term funding initiatives to provide the required capital to achieve these initiatives. Recent achievements and planned initiatives at Bibiani include: Exploration of near mine targets proved to be successful with the Grasshopper satellite pit coming into production in Q2 2023. At the South Russel deposit, a starter pit is planned to be developed during Q4 with delivery of mineralized material expected to occur by January 2024; The gravity plant was upgraded prior to start of production in July 2022 and continues operation achieving 25 - 35% gold recovery, as planned. The installation of a scalping screen is planned to increase gravity gold recovery by 5% with expected completion in late October 2023; The oxygen plant, installed on schedule, has been providing oxygen to the process plant from September 2023. Installation of a Mach-reactor to increase oxygen utilization will be completed this week; A pebble crusher has been ordered and will be installed in the coming months to increase process plant throughput capacity from 3.0 million to 3.4 million tonnes per year; The Sulphide Recovery Plant long lead items are expected to ship in September 2023. Construction of the plant is planned to be five months from the time of delivery to site. When in operation, the Sulphide Recovery Plant is expected to improve gold recovery to over 90%; Construction of the planned detour road is nearly complete allowing the highway to be cut and providing access to higher grade mineralized material from the main pit by early 2024; and Other cost saving and productivity improvement initiatives have started with implementation planned over the coming months. For the fiscal year ending January 31, 2024, the Company expects production of approximately 80,000 to 90,000 ounces gold at Bibiani. Subject to receipt of the requisite funding and completion of capital projects as outlined above, Asante expects Bibiani to produce approximately 180,000 ounces of gold for the fiscal year ending January 31, 2025 with all-in sustaining costs of $1,325/oz. The Chirano process and mine facilities are operating on a 24 hour per day basis at a current throughput of approximately 3.6M tonnes per year. Recent achievements and planned initiatives at Chirano include: Gravity plant design, procurement and installation is advanced, with completion expected in October 2023 to increase gold recovery at Chirano by 5%; Oxygen addition to the CIL plant is proceeding and the oxygen plant is planned for installation prior to November 30, 2023; A pebble crusher was procured and installed on schedule in May 2023 increasing plant throughput from 3.4 million to 3.6 million tonnes per year; Further primary grinding upgrades are planned to be operational late this year to increase process plant throughput from 3.6 million to 4.0 million tonnes per year; Relocation of minor infrastructure and facilities planned to provide access to and expansion of the Akoti South open pit and the second cutback at the Sariehu open pit is progressing well; Mining from the Mamnao central and south pits is expected to be completed during Q3 2024. This production is expected to be replaced by Sariehu and Mamnao north pits. These initiatives would provide access to incremental resources and sustained gold production; Studies and associated initiatives are progressing on schedule to be finalized late 2024, with design to improve the current material handling systems and to deliver mineralized material to the process plant at lower cost; Initiatives to capture synergies to yield benefits related to the supply of principal consumable materials between the Bibiani and Chirano mines are being advanced with an overall objective of saving approximately $10 million per year; Other cost saving and productivity improvement initiatives have advanced, with results expected to be achieved later this year; Development of Obra, Suraw and the lower Tano underground mines have been accelerated facilitating earlier than planned underground mining at the Obra mine which supplements plant feed and has improved the grade from 1.2 g/t to 1.6 g/t for the year to date; and Exploration projects such as the Suraw mine, Obra mine and open pit mining life extension projects at the Sariehu/Mamnao area are progressing as planned to support a robust mining program and extend the mining life. For the fiscal year ending January 31, 2024, the Company expects production of between 145,000 and 155,000 ounces of gold at Chirano. With the execution of the foregoing initiatives, the Company is projecting production of approximately 180,000 ounces of gold for the fiscal year ending January 31, 2025 at all-in sustaining costs of approximately $1,250/oz. See footnote 2 below for assumptions. The Company continues to focus on the execution of its near-term growth plans and financing initiatives, including discussions with potentially interested parties regarding strategic alternatives.

08:25 EDT ParaZero to showcase its drone safety systems at DroneX Tradeshow - ParaZero Technologies announced its participation in the DroneX Tradeshow & Conference, set to take place on September 26th & 27th, 2023, at the ExCeL London venue. The show promises to be a melting pot of innovation, offering an international stage for professionals interested in the latest advancements in Unmanned Aerial Vehicle and urban air mobility technologies. Visitors to the ParaZero booth will be treated to live demonstrations and interactive presentations detailing the company's category-defining drone safety systems. ParaZero will present at booth J72, showcasing the latest developments in ParaZero safety technology for support of UAS and UAM aircraft in the 1kg to 1000kg MTOW weight classes, as well as available support for advanced global regulatory compliance needs, including SORA-based approvals, type certification processes, ASTM F3322 projects, personal eVTOL safety, and more.

08:22 EDT Akari Therapeutics enters definitive purchase agreements with existing investors - Akari Therapeuticshas entered into definitive purchase agreements with certain existing investors, including Akari Chairman Dr. Ray Prudo and President and CEO Rachelle Jacques, for a private placement of its equity securities that is expected to result in gross proceeds of approximately $2 million. Akari also announced receipt of a United Kingdom research and development tax credit in the amount of $2.5 million. In connection with the private placement financing, the Company will issue unregistered American Depository Shares, each representing 2,000 of the Company's ordinary shares, at a purchase price of $3.30 per ADS. The closing of the financing is expected to take place September 22, 2023, subject to the satisfaction of customary closing conditions. Paulson Investment Company, LLC, is acting as the exclusive placement agent in connection with this financing.

08:20 EDT Wearable Devices' Mudra Band to leverage new Apple Watch 'DoubleTap' feature - Wearable Devices announced that Apple's new double tap feature, unveiled with the new Apple Series 9 Watch, is expected to further enhance the utility and consumer experience of Wearable Devices' Mudra Band. The combination is expected to empower improved touchless control across the Apple product ecosystem, leveraging Wearable Devices' cutting-edge Air-Touch technology. Wearable Devices expects that Mudra Band users will be able to leverage its cutting-edge Air-Touch technology with the newly revealed Apple Watch Double Tap gesture, to gain full touchless control across the entire Apple product ecosystem by utilizing the Mudra Band gestures in tandem with the Apple Watch Double Tap gesture. The Company anticipates that users will be able to enhance their productivity and user experience by touchlessly navigating the unique Mudra Band Watch Face, toggle and switch the control to another Apple ecosystem device, and use Air-Touch gestures to touchlessly control the iPhone, iPad, Mac and AppleTV products.

08:18 EDT Dare Bioscience will receive a payment of $4.5M under grant agreement - Dare Bioscience announced it will receive a payment of approximately $4.5M as the latest installment under a grant agreement to advance the development of Dare's investigational contraceptive DARE-LARC1 through nonclinical proof of principle studies and other IND-enabling work to allow for the submission of an Investigational New Drug Application with the FDA, approval of which will be required to commence testing in humans. Under the terms of the grant agreement, Dare may receive a total of up to approximately $49 million to support nonclinical development of DARE-LARC1. Dare received an initial $11.5 million payment in 2021 and aggregate payments of approximately $12.4 million in 2022 under the grant agreement. Additional payments are conditioned on the program meeting specified development and reporting milestones. "The DARE-LARC1 product candidate is one of a number of novel contraceptive technologies being developed by Dare," said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. "In addition to advancing important pre-clinical activities to support the DARE-LARC1 program, we're also excited to continue the late-stage development of Ovaprene(R), our investigational hormone-free monthly intravaginal contraceptive that is designed to be worn conveniently over multiple weeks, or one menstrual cycle. We are on track to begin patient enrollment in the fourth quarter of this year in the planned pivotal Phase 3 clinical trial of Ovaprene being conducted in collaboration with NICHD."

08:17 EDT Heart Test Laboratories signs agreement with Icahn School of Medicine - Heart Test Laboratories announced it has executed definitive agreements with the Icahn School of Medicine at Mount Sinai, in New York, NY, to commercialize electrocardiographic AI algorithms and assets, as well as a memorandum of understanding for on-going cooperation, collaboration and de-identified data access. Icahn Mount Sinai has invested in the curation of tens of millions of ECG records, enabling its leading researchers to develop a range of disease detection algorithms and state-of-the art AI foundational methods for use with ECG waveforms. HeartSciences has entered into licenses covering rights to a variety of Icahn Mount Sinai's AI algorithms, technologies and patent filings for the screening and diagnosis of cardiovascular disease. HeartSciences and Icahn Mount Sinai have also entered into a memorandum of understanding for ongoing cooperation encompassing de-identified data access, on-going research, and the evaluation of HeartSciences' MyoVista wavECGTM. "We are thrilled to announce this agreement with Icahn Mount Sinai and look forward to working with one of the top-ranked hospitals for cardiology in the world, at the cutting edge of AI-powered ECG development," said Andrew Simpson, CEO of HeartSciences. "This is a transformative event for the Company and will significantly strengthen our business, accelerate our development and broaden the range of prospective solutions that we will provide for patients.

08:13 EDT Hepion Pharmaceuticals announces results from study of rencofilstat - Hepion Pharmaceuticals announced results from a study with in which the anti-cancer activity of Hepion's lead drug candidate, rencofilstat, was tested in a high through-put screen on 850 cancer cell lines spanning 28 types of cancer at the PRISM lab at the Broad Institute of MIT and Harvard. Rencofilstat was administered at eight concentrations to each cancer cell line in culture for 5 days, followed by measurement of surviving cells to determine how effectively the drug candidate killed or suppressed proliferation of the cancer cells. Defining "anti-cancer responsiveness" as 50% or greater reduction in viability following treatment, 26% of all tested cancer cell lines spanning 86% of cancer cell types were responsive to rencofilstat. Some of the rencofilstat-sensitive cell lines were HCC cells, which further supports Hepion's plans for a clinical trial in this indication. Furthermore, the reductions in viability in responsive cells occurred at drug concentrations similar to those observed in individuals participating in Hepion's NASH clinical trials. Thus, administration of rencofilstat to cancer patients with the standard regimen of once-daily oral dosing may be efficacious for those with responsive types of cancer. The screening study also integrated additional information collected by the Broad Institute about the cancer cell lines, such as gene mutations, gene expression, and protein and metabolic profiles, to provide insights into rencofilstat's mechanisms of action and identify biomarkers associated with its anti-cancer activity. Some of the markers uncovered by these analyses were related to familiar rencofilstat mechanisms, whereas others pointed to new processes. Genes known to be mutated in HCC or other types of cancer, including ATM, PTPRB, HNF1A, NOTCH1, ALK, TP63, IDH2 and MAP3K, were among the many genes identified to possibly influence the sensitivity of cells to rencofilstat.

08:12 EDT Cyclo Therapeutics, Applied Molecular Transport announce merger deal - Cyclo Therapeutics (CYTH) and Applied Molecular Transport (AMTI) that the companies have entered into a definitive agreement pursuant to which AMT will merge with Cyclo Therapeutics in an all-stock transaction . Following the closing of the Merger, the combined company will operate under the name "Cyclo Therapeutics, Inc." and will continue trading on The Nasdaq Capital Market under the ticker symbol "CYTH". The combined company will focus on advancing Cyclo Therapeutics' pivotal Phase 3 global study or TransportNPC evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1. The transaction is currently expected to close in the fourth quarter of 2023. Shawn Cross, CEO of AMT added, "Following an extensive and thorough strategic review process, we view this merger with Cyclo Therapeutics as the best path forward for AMT shareholders given the promise and potential of its late-stage program in NPC1. We are encouraged by the progress shown in this important program and Cyclo Therapeutics' long-standing support of NPC1 patients and their families in its compassionate use program. Cyclo Therapeutics has continued to demonstrate its commitment to developing life-changing medicines and execution across clinical and regulatory fronts. Our board and management believe the company is well positioned to unlock significant value and successfully advance Trappsol Cyclo through the on-going pivotal trial and ultimately to approval with the goal of providing a safe, convenient and effective alternative for people who are living with a debilitating disease." Under the terms of the Merger Agreement, AMT stockholders will receive approximately 0.174 shares of Cyclo Therapeutics in exchange for each of their shares in AMT . Cyclo Therapeutics expects to issue approximately 7.624 million shares of Cyclo Therapeutics' common stock to AMT shareholders, equating to approximately 25% of the combined company on a fully diluted basis. The combined company will be led by the existing Cyclo Therapeutics management team and will be headquartered in Gainesville, FL. Subsequent to the closing of the transaction, Shawn Cross, Chief Executive Officer and Board Chair of AMT will be appointed to the Cyclo Therapeutics Board of Directors. The Merger has been approved by the board of directors of each company and is currently expected to close in the fourth quarter of 2023, subject to the satisfaction or waiver of customary conditions, including the requisite approval by Cyclo Therapeutics' and AMT's stockholders and the effectiveness of a registration statement on Form S-4 to register the shares of Cyclo Therapeutics common stock to be issued in connection with the transaction. As the transaction proceeds, the parties will publicly disclose required information either through press releases or filings with the Securities and Exchange Commission , as appropriate.

08:10 EDT Visionary Education Technology appoints new COO, diversifies busine structure - Visionary Education Technology Holdings has decided to diversify its business into three sectors: Education, Life Sciences, and Artificial Intelligence. In addition, the Board has appointed Charlie Penn as COO, effective September 14. The company is expanding its business to reflect its focus on the new generation of Education, AI and Life Science, including the expansion into life sciences for a future synergy from breakthroughs in technology. The Board has appointed Charlie Penn to serve as COO. In 1999, he invested in Canada Princeton College and served as an executive director. Penn also engaged in industrial real estate investment in 2007 and served as the Executive Director of Birmingham Holdings and the Executive Director of English Premier League Football Club in 2013, responsible for the management of the listed company's business and sports real estate operations.

08:08 EDT Enphase Energy launches new home energy systems in U.K. - Enphase Energy announced the launch of its most powerful Enphase Energy System to-date, featuring the new IQ Battery 5P and IQ8 Microinverters, for customers in the United Kingdom. The IQ Battery 5P is modular with 5 kWh capacity; the new IQ8 Microinverters provide a peak AC output power of 384 W to support high-powered solar modules, offering homeowners resilient and reliable electricity. The new Enphase storage system starts at 5 kWh of capacity and can be configured with multiple batteries up to 60 kWh. The third-generation Enphase Energy System offers a significantly improved experience for homeowners and installers because of more power, resilient wired communication, and an improved commissioning experience.

08:06 EDT Avantor announces creation of new Scientific Advisory Board - Avantor announced the creation of a new Scientific Advisory Board which will provide strategic guidance and consult on the company's mid- to long-term research and development efforts to deliver solutions for the life sciences industry, including biotech and pharma customers. The SAB brings deep knowledge and experience in clinical research, academia, and industry to Avantor, and a passion for advancing science that improves health and well-being. By bringing together experts with a track record of working across innovative modalities, the SAB will enable Avantor to better serve customer needs as well as emerging opportunities and challenges facing the life sciences industry.

08:05 EDT Orgenesis' Octomera, CGT Global enter agreement - Orgenesis continues to grow the Point of Care network and infrastructure of its advanced therapeutic services and facilities business through its subsidiary Octomera, by partnering with CGT Global, a biomedical company dedicated to advancing medical science and patient therapies. The two companies are collaborating to leverage CGT Global's extensive network of CGT Clinics and Healthcare partnerships to expand commercialization of CGTs in California and other US locations. Resources will be aligned to place technology-agnostic Octomera Mobile Processing Units & Labs for leukapheresis and the production of CAR-T and TILS products. The Company expects the footprint to grow as CGT Global partners with 32 hospitals today and anticipates partnering with over 200 hospitals by the end of 2024. CGT Global will provide expertise gained from being a leading provider of cellular manufacturing, biomedical therapeutic collections, and services through their existing network of CGT Clinics and hospital footprint. Octomera will provide services and support, as well as placement of agnostic OMPULs that are designed to standardize CGT production processes for quality and regulatory compliance across the globe at a fraction of the cost.

08:05 EDT Quantum Computing choses Tempe, Arizona for quantum photonic chip foundry - Quantum Computing announces that it has chosen ASU Research Park in Tempe, Arizona, as the location for its new quantum photonic chips manufacturing facility, where it will produce its Thin Film Lithium Niobate chips. To date, QCi has placed deposits for the procurement of critical long-lead equipment and paid other expenses associated with the new chip fabrication facility of approximately $2M. The company plans to begin the buildout of the facility during fourth quarter 2023.

08:03 EDT Spire appoints Steve Lindsey as President and CEO - Spire has named Steven L. Lindsey, who currently serves as EVP and COO, as President and CEO, and has appointed him to its Board of Directors, effective October 1. He will succeed Suzanne Sitherwood who announced earlier this year her intention to retire at the end of December. Prior to his 11 years in executive roles with Spire, he spent 23 years in the natural gas utility business at AGL Resources, most recently serving as president of Atlanta Gas Light, Chattanooga Gas and Florida City Gas and as senior vice president of southern operations.

08:03 EDT Leidos awarded new prime contract worth $74M - Leidos was recently awarded a new prime contract to provide combined joint all-domain command and control analysis and support to the U.S. Department of Defense Joint Staff J6 Joint Assessment Division. The cost-plus-fixed-fee, single-award contract has a period of performance of five years and six months. The contract has an approximate value of $74M.

08:00 EDT Applied Molecular Transport trading halted, news pending

07:47 EDT Cisco to acquire Splunk for $157 per share in cash, or $28B EV - Cisco (CSCO) and Splunk (SPLK) announced a definitive agreement under which Cisco intends to acquire Splunk for $157 per share in cash, representing approximately $28B in equity value. Upon close of the acquisition, Splunk President and CEO Gary Steele will join Cisco's Executive Leadership Team reporting to Chair and CEO Chuck Robbins. The transaction is expected to be cash flow positive and gross margin accretive in the first fiscal year post close, and non-GAAP EPS accretive in year two. Additionally, it will accelerate Cisco's revenue growth and gross margin expansion. The transaction will not impact Cisco's previously announced share buyback program or dividend program. The acquisition has been unanimously approved by the boards of directors of both Cisco and Splunk. It is expected to close by the end of the third quarter of calendar year 2024, subject to regulatory approval and other customary closing conditions including approval by Splunk shareholders.

07:42 EDT Electrovaya expects to increase engineering staffing by 50% in 2023 - Electrovaya announced a business update. The company said, "Electrovaya has made incremental improvements in its manufacturing process, equipment and facilities over the last several months that have led to increased capacity and efficiency. The Company believes that the overall manufacturing capacity at its 6688 Kitimat Road location in Mississauga, Ontario has nearly doubled year to date, with an annual capacity of approximately $130 million of battery systems. Given the capacity improvements, the Company continues to operate a single shift to meet its production goals. The Company believes that there are further optimizations available, including through additional automation and equipment, and intends to pursue these opportunities. Electrovaya has applied for Canadian government funding to support these potential further investments. Electrovaya is growing its engineering capabilities significantly. The Company expects that its engineering staffing will increase by approximately 50% in 2023, with most of the targeted additions on-boarded over the past three months. The additional staff brings expertise in many engineering disciplines, including firmware, software, mechanical engineering, industrial engineering and electrical engineering. With the expanded team, Electrovaya expects to have the capability to execute on additional OEM projects for both low-voltage and high-voltage applications, and to develop new products, from battery systems to value added software. The Company is also planning to hire additional staff to support cell manufacturing activities, and recently hired a General Manager for its Jamestown, New York facility. Electrovaya continues to execute on growing deliveries in the material handling vehicle industry. The Company recently made shipments to Australia, received its first orders from Asia, and received a new order from its largest Fortune 100 end user, which already uses the Company's batteries at 14 of its facilities and now plans to use them in a 15th. There continues to be strong interest in Electrovaya's newest high voltage offerings and are targeting the transit, mining, defense and other heavy duty vehicle applications. The Company is on track to ship its first pre-production systems this calendar year. Electrovaya's management team remains confident in the Company's ability to execute on its strategy and continue to build a strong and sustainable growth trajectory. Both Dr. Raj DasGupta, CEO, and John Gibson, CFO, have recently purchased shares on the open market, underscoring their confidence in the Company."

07:37 EDT PolyPid announces 'successful' GMP audit by Israeli Ministry of Health - PolyPid announced that the Israeli Ministry of Health has completed a successful Good Manufacturing Practice audit of the Company's manufacturing facility without any critical or major findings. The audit was conducted as part of the Ministry of Health's routine evaluation of PolyPid's manufacturing process for D-PLEX100. The audit concluded that PolyPid's manufacturing facility, process and quality system conform to the requirements of current GMP for medicinal products. This audit is also valid for Europe under the provisions of the Agreement on Conformity Assessment and Acceptance of industrial products (ACAA) between the European Union and Israel.

07:36 EDT Dragonfly Energy becomes member of BMTC - Dragonfly Energy Holdings is the newest member of the Battery Materials and Technology Coalition, BMTC. The BMTC is a continental alliance of member companies united behind a shared interest in growing a resilient and sustainable North American battery supply chain. "By joining the BMTC and partnering with the coalition's other industry leaders during this rapidly growing global battery economy, we continue to drive meaningful conversations and make significant contributions toward the evolution of the energy storage sector," said Dominic Sinnott, director of government affairs at Dragonfly Energy. "We are proud to become a member of this remarkable coalition dedicated to solidifying North America's critical role in the global battery ecosystem."

07:36 EDT Nauticus Robotics announces term loan financing up to $20M - Nauticus Robotics has entered into a senior secured term loan agreement with existing stakeholders, Transocean, ATW Partners, Material Impact, and RCB Equities. The Term Loan Agreement provides Nauticus with up to $20 million in secured term loans, of which $11.6 million has already been funded. The Loans are convertible at $6.00 per share of common stock, subject to certain customary anti-dilution adjustments as described in the Term Loan Agreement, at the option of each Lender, until the date that the Loans are no longer outstanding. The Company is actively discussing a larger round of capital with new investors, beyond the available capacity of the Term Loan Agreement, to support its service offering expansion.

07:35 EDT Ocugen appoints Connie Collingsworth to Business Advisory Board - Ocugen announced that Connie Collingsworth, former COO of the Bill and Melinda Gates Foundation, will join the Company's Business Advisory Board. The BAB was established in June 2023 to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company's differentiated capabilities; and promoting access to the Company's therapies around the world.

07:32 EDT Sensei Biotherapeutics presents preclinical data on SNS-101 - Sensei Biotherapeutics will present new preclinical data from SNS-101 at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held on September 20 - 23, 2023 in Milan, Italy. "We believe these data further support the potential best-in-class PK and safety profile of SNS-101 and its ability to effectively target VISTA, a promising, but difficult-to-drug immune checkpoint," said Edward van der Horst, Ph.D., Chief Scientific Officer of Sensei Biotherapeutics. "Restricting drug activity to low pH conditions, such as those found in the acidic tumor microenvironment, allowed us to safely dose SNS-101 in our multi-dose NHP study at increasing levels while maintaining linear elimination kinetics and displaying no target-mediated drug disposition or adverse effects. Paired with new mechanistic data showing SNS-101 can shift immunosuppressive macrophages towards an anti-tumor phenotype, we believe SNS-101 could provide a transformative treatment option for patients. We look forward to sharing data from our ongoing clinical trial later this year." Presentation Highlights: SNS-101 displayed linear elimination kinetics and no target-mediated drug disposition or adverse effects in a multi-dose GLP toxicology study in cynomolgus monkeys evaluating SNS-101 doses of 1, 10 and 100 mg/kg. In MC38 tumor-bearing mice, SNS-101 alone and in combination with an anti-PD-1 antibody shifted the cytokine expression profile of immunosuppressive myeloid cells in the tumor microenvironment to an anti-tumor, M1 phenotype. The expression of anti-tumor cytokines was correlated with a reduction in tumor size.

07:19 EDT Draganfly announces grand opening of Saskatoon production facility - Draganfly announced the grand opening of its new manufacturing and production facility in Saskatoon, which will take place on September 26, 2023. The opening of this new facility will help Draganfly achieve its commitment to meet the increasing market potential for its products and solutions. The Saskatoon facility has been designed to meet the rising demand for Draganfly's UAV systems and components, such as the Heavy Lift, Commander 3 XL, Commander XL Hybrid and its new Precision Delivery System. This facility will help advance manufacturing capabilities, streamline assembly processes, deepen R&D capabilities, and optimize integration procedures.

07:18 EDT Augmedix announces inaugural AI Advisory Council members - Augmedix announced the appointment of its inaugural AI Advisory Council members. The council was established to guide Augmedix's continued development and usage of artificial intelligence throughout its business responsibly and ethically. The council is led by Joe Marks, Ph.D., a former Augmedix board member who served as director of the Company from 2020 until 2023. Dr. Marks was previously the Executive Director of Carnegie Mellon University's Center for Machine Learning and Health and has established himself as a technological innovator in seven different industries over the past 30 years. Council members are esteemed professionals and leaders from various fields and are appointed for 18 months. The newly appointed members of the council are: Julia Adler-Milstein, Ph.D., Chief of the Division of Clinical Informatics and Digital Transformation at University of California San Francisco; Albert Chan, M.D., Chief Digital Health Officer, Sutter Health; John Chelico, M.D., M.A., FACP, FAMIA, System CMIO for CommonSpirit Health; John Doulis, M.D., VP Data Services and Technology Innovation at HCA Healthcare; Jesse Ehrenfeld, M.D., MPH, President of the American Medical Association; Joe Marks, Ph.D., AI Advisory Council Chair; Eric Nyberg, Ph.D., Professor at Carnegie Mellon University School of Computer Science Language Technologies Institute; Lisa Rotenstein, M.D., MBA, MSc, Assistant Professor at Harvard Medical School and Medical Director of Population Health at Brigham and Women's Hospital; Sameer Singh, Ph.D., Associate Professor of Computer Science at UC Irvine; Alex Stinard, M.D., Healthcare Information Technology Consultant at HCA Healthcare.

07:15 EDT Green Thumb appoints Richard Reisin, Hannah Ross to board of directors - Green Thumb Industries announced that Richard Reisin and Hannah Ross have been appointed to its Board of Directors as independent members, effective September 20, 2023. Reisin will serve on the audit committee and Ross will serve on the audit and compensation committees of the Board. The appointments bring the Company's Board of Directors to a total of nine members. Reisin formerly served as Executive Vice President and Director at Carylon Corporation. Ross is the COO of Edie Parker.

07:08 EDT Tonix Pharmaceuticals presents new preclinical data from CICON23 - Tonix Pharmaceuticals announced a poster presentation showing research results for mTNX-1700 at the Seventh International Cancer Immunotherapy Conference 2023, CICON23,: Translating Science into Survival, being held September 20-23, 2023, in Milan, Italy. The poster presentation, titled, "mTFF2-MSASuppresses Tumor Growth and Increases Survival in Anti-PD-1 Treated CT26.WT Subcutaneous and CT26-Luciferase Orthotopic Syngeneic Colorectal Cancer Models by Targeting MDSCs in BALB/C Mice," includes data demonstrating that the novel fusion protein, mTNX-1700 has single agent activity and can improve on the therapeutic effects of anti-PD-1 in treating syngeneic mouse models of advanced colorectal cancer. In two models, mTNX-1700 increases survival rates and suppresses tumor growth. "mTNX-1700 is a novel fusion protein that has single agent activity and augments PD-1 blockade therapy in combination therapy in advanced and metastatic syngeneic mouse models of colorectal and gastric cancer," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "Certain cancers are unresponsive to anti-PD-1 therapy. Despite the significance of PD-1 checkpoint blockade in treating many types of cancer, there's a need to better understand why some cancers don't respond and how to make them responsive. We believe these data show the potential of TNX-1700 in treating cancer both as a single agent and in combination with other immuno-oncology drugs, particularly anti-PD-1, and highlight how mTNX-1700 targets MDSCs as a novel mechanism to treat cancer."

07:07 EDT Helius to bring PoNS therapy to 2023 Neurologic Physical Therapy conference - Helius Medical Technologies announced that it will exhibit at the Academy of Neurologic Physical Therapy 2023 Annual Conference, September 28-30 at the Hyatt Regency Minneapolis, marking its first appearance at the conference. The Company's focus at booth 7 will be its innovative Portable Neuromodulation Stimulator, an orally applied therapy delivered by translingual neurostimulation to improve gait deficit in people with multiple sclerosis.Helius' debut at the conference is timely, coming just after National Rehabilitation Awareness Week and on the eve of National Physical Therapy Month. "The calendar is spotlighting rehabilitation and physical therapy right now, and we're enthused to keep the conversation going with ANPT conference attendees," said Helius' Chief Medical Officer, Antonella Favit-Van Pelt, M.D., Ph.D. "Among the specialists who treat multiple sclerosis, the neurologic physical therapists understand the challenges in addressing gait deficit in people with MS better than anyone. We strive to have all who visit us at the booth walk away from the conference with a thorough knowledge of PoNS technology and therapy, as well as an appreciation of the impact they have in the lives of people with MS by offering a new therapeutic option to their patients."

07:04 EDT Medtronic's Simplera glucose monitor granted CE Mark - Medtronic announced CE - Conformite Europeenne - Mark approval for its new all-in-one, disposable Simplera continuous glucose monitor - CGM - featuring a simple, two-step insertion process. The company's newest no-fingerstick sensor does not require over tape and is integrated with the InPen smart insulin pen, which provides real-time, personalized dosing guidance to help simplify diabetes management. Medtronic will begin a phased launch at the European Association for the Study of Diabetes Meeting in Hamburg, Oct. 2-6. Simplera is indicated for ages 2+ and compatible with iOS and Android. Simplera is not approved by the FDA and is limited to investigational use in the U.S.

07:03 EDT Entrada announces first patient dosed in Phase 1 trial of ENTR-601-44 - Entrada Therapeutics announced that the first participant has been dosed in its Phase 1 clinical trial evaluating ENTR-601-44 for the potential treatment of individuals with Duchenne muscular dystrophy who are exon 44 skipping amenable. "The initiation of our Phase 1 trial for ENTR-601-44 is an important step forward in addressing this relentlessly progressive neurodegenerative disease," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Today's announcement marks Entrada's transition into a clinical company. As we enter our next phase of growth, Entrada is well-positioned to advance this initial program, as well as our broader Duchenne franchise, and we expect to report data from the Phase 1 trial in the second half of 2024." The primary objective of Entrada's Phase 1 clinical trial, which is being conducted in the United Kingdom, is to evaluate the safety and tolerability of a single dose of ENTR-601-44 in healthy male volunteers, with a target enrollment of approximately 40 participants. The trial will also evaluate pharmacokinetics and target engagement, as measured by exon skipping in the skeletal muscle.

07:01 EDT Palantir's Artificial Intelligence Platform selected by CAZ Investment - Palantir and CAZ Investments announced a 5-year partnership for Palantir to provide its Artificial Intelligence Platform in support of CAZ's growth and innovation. Palantir will provide CAZ with AI-powered solutions to accelerate partner onboarding and augment investment managers' work with generative AI. The use of Palantir's software aims to help CAZ automatically scale operations and meet growing demand. CAZ Investments' proprietary research process and global network identifies thematic investment opportunities across public and private markets.

06:49 EDT W&T Offshore acquires producing properties in Gulf of Mexico for $32M - W&T Offshore has completed the acquisition of working interests in eight shallow water oil and gas producing assets in the central and eastern shelf region of the Gulf of Mexico from an undisclosed private seller. The acquisition has a closing date of September 20, and an effective date of June 1. The Assets were acquired for a gross consideration of $32M, subject to normal and customary post-effective date purchase price adjustments. W&T used its cash on the balance sheet to pay the net purchase price. Highlights of the transaction include: average working interest of around 72%; includes estimated production as of September 12, 2023, of approximately 2,400 barrels of oil equivalent per day, 42% oil - around two thirds of the production is operated; adds proved reserves of 3.2 million barrels of oil equivalent - 49% oil - and accretive gross purchase price multiple of approximately 1.0x last twelve months cash flows as of effective date and production multiple of approximately $13,500 per barrel of oil equivalent per day. The Assets include 30,646 gross acres and are currently producing approximately 2,400 barrels of oil equivalent per day, of which 42% is oil. Estimated proved reserves as of June 1, 2023, for the eight properties totaled 3.2 million barrels of oil equivalent (49% oil) of which 100% are proved developed. The 2P reserves for the acquired properties are estimated to be 5.1 million barrels of oil equivalent, 48% oil.

06:43 EDT Clear Secure launches identity verification technology at BUF - Clear Secure announced it is launching its identity verification technology at Buffalo Niagara International Airport's, or BUF, Main Terminal, bringing frictionless and predictable travel experiences to Upstate New York. Clear's launch at BUF is expected to create 28 jobs and generate approximately $1.5M annually in local economic impact.

06:38 EDT Parsons awarded $160M contract by the Intelligence Community - Parsons announced that the company was awarded a competitively-bid, single-award $160M contract by the Intelligence Community to develop hardware and software solutions that enable intelligence applications. The classified contract includes a one-year base period plus six one-year option periods.

06:10 EDT Toshiba shareholders approve roughly $14B deal to take company private - Toshiba said Thursday that a nearly $14B tender offer from private equity firm Japan Industrial Partners ended successfully. The company said about 79% of its shareholders tendered their shares at the offered price of Y4,620 a share. Reference Link

06:03 EDT Aurinia Pharmaceuticals enters cooperation agreement with MKT Capital - Aurinia Pharmaceuticals announced that its Board of Directors has appointed Dr. Robert Foster to the Board. MKT Capital submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board. In connection with Dr. Foster's appointment, MKT Capital has entered into a cooperation agreement with Aurinia. A complete copy of the cooperation agreement will be available on EDGAR and SEDAR.

05:56 EDT Uber Eats to start accepting food stamps for grocery delivery in 2024 - Uber Eats will start accepting food stamps and healthcare benefits as payment for grocery delivery orders, the company announced Wednesday. It also plans to add a new AI assistant that it says will help grocery customers get better deals. "We know that online food delivery can have a meaningful impact in reducing barriers to fresh groceries, especially for the most vulnerable-including people living in food deserts, seniors, and those facing disabilities or transportation barriers," Therese Lim, senior director of product at Uber Eats, said in a blog post. Reference Link

05:16 EDT JetBlue adds Amsterdam service from Boston - JetBlue has expanded its Amsterdam service with new nonstop flights between Boston Logan International Airport, or BOS, and Amsterdam Airport Schiphol, or AMS, taking off today, following the successful launch of service from New York's JFK Airport, or JFK, on August 29. From JetBlue's Boston focus city, the carrier also offers daily service to London and in 2024 will launch service to Paris.

05:12 EDT Powerbridge announces 1-for-8 share consolidation - Powerbridge announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective as of 5:00 p.m. Eastern Time on September 21. The company's ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session at 4:00 a.m. Eastern Time on September 22. Upon the opening of the market session on September 22, the company's ordinary shares will continue to be traded on Nasdaq with the new CUSIP number G72007126. As a result of the share consolidation, every eight shares of the company's ordinary shares will be automatically consolidated into one ordinary share. The Share consolidation will not modify any rights of the ordinary shares of the company. No fractional shares will be issued in connection with the share consolidation, all such fractional shares shall be redeemed in cash for the fair value of such fractional share, which is based on the closing price of the ordinary shares on a post-consolidation basis on Nasdaq on the first trading date of the ordinary shares following the share consolidation.